

**S2 Table.** Clinicopathologic characteristics of study population according to the line of chemotherapy

Characteristic	Total (n=189)	3rd line chemotherapy (n=41)	4th line chemotherapy (n=54)	5th line chemotherapy (n=94)	p- value
Age at initial diagnosis (yr)	54.0±10.8	54.2±10.9	52.0±12.3	54.2±9.8	0.441
Histologic type					0.085
Serous	148 (78.3)	30 (73.2)	43 (79.6)	75 (79.8)	
Endometrioid	15 (7.9)	3 (7.3)	1 (1.9)	11 (11.7)	
Clear cell	13 (6.9)	3 (7.3)	5 (9.3)	5 (5.3)	
Mucinous	7 (3.7)	2 (4.9)	4 (7.4)	1 (1.1)	
Mixed	3 (1.6)	1 (2.4)	0 (0.0)	2 (2.1)	
Undifferentiated	2 (1.1)	1 (2.4)	1 (1.9)	0	
Others	1 (0.5)	1 (2.4)	0	0	
Grade					0.614
1	5 (2.6)	1 (2.4)	3 (5.6)	1 (1.1)	
2	20 (10.6)	6 (14.6)	7 (13.0)	7 (7.4)	
3	156 (82.5)	33 (80.5)	42 (77.8)	81 (86.2)	
Undifferentiated	1 (0.5)	0	0	1 (1.1)	
Unknown	7 (3.7)	1 (2.4)	2 (3.7)	4 (4.3)	
FIGO stage					0.159
I	8 (4.2)	2 (4.9)	5 (9.3)	1 (1.1)	
II	7 (3.7)	2 (4.9)	1 (1.9)	4 (4.3)	
III	118 (62.4)	22 (53.7)	36 (66.7)	60 (63.8)	
IV	56 (29.6)	15 (36.6)	12 (22.2)	29 (30.9)	
Results of initial debulking surgery					0.527
No residual tumor	92 (48.7)	20 (48.8)	27 (50.0)	45 (47.9)	
Residual tumor < 1 cm	58 (30.7)	11 (26.8)	20 (37.0)	27 (28.7)	
Residual tumor ≥ 1 cm	39 (20.6)	10 (24.4)	7 (13.0)	22 (23.4)	
CA-125 at baseline (IU/mL)	809.0 (3-24,720)	1007.0 (46-24,720)	639.0 (3-4,620)	830.0 (7-11,230)	0.093
Age at the latest recurrence (yr)	56.9±10.9	56.4±10.7	55.3±12.7	58.2±9.8	0.281
CA-125 at the latest recurrence (IU/mL)	164.5 (3-7,700)	107.5 (6-3,414)	120.0 (3-6,490)	242.5 (6-7,700)	0.838
TFI (mo)	1.38 (0.3-93.1)	1.08 (0.5-93.1)	2.00 (0.6-46.1)	1.28 (0.3-42.8)	0.522

Values are presented as mean±SD, number (%), or median (range). CA-125, cancer antigen 125; FIGO, International Federation of Gynecology and Obstetrics; SD, standard deviation; TFI, treatment-free interval.